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Summary
Objective: To evaluate the relationship between specific cleavage of aggrecan at the Glu373–Ala374 ‘aggrecanase’ site
and degradation and release of proteoglycan catabolites from cartilage in explant cultures.
Design: The monoclonal antibody, BC-3, which specifically recognizes the new N-terminus, ARGSVIL, generated by
cleavage of aggrecan at the Glu373–Ala374 ‘aggrecanase’ site, was used to follow the generation of fragments produced
by cleavage at this site as compared to degradation of proteoglycan as assessed by glycosaminoglycan (GAG) release
from cartilage in response to cytokines and the ability of inhibitors to block this cleavage.
Results: (1) There was a strong correlation between specific cleavage at the Glu373–Ala374 bond and the release of
aggrecan catabolites in response to interleukin-1 (IL-1) or tumour necrosis factor (TNF) stimulation. (2) This cleavage
in the interglobular domain of aggrecan was inhibited by the inclusion of cycloheximide, thus indicating a requirement
for de novo protein synthesis in the induction of ‘aggrecanase’ activity. (3) The inhibitors, indomethacin, naproxen,
tenidap, dexamethasone and doxycycline were ineffective in blocking either specific cleavage at the ‘aggrecanase’ site
or aggrecan degradation as measured by GAG release from cartilage. (4) In contrast, compounds which act through
two different mechanisms to inhibit MMPs were effective in blocking both specific cleavage at the ‘aggrecanase’ site
and proteoglycan degradation.
Conclusions: Our data suggest that ‘aggrecanase’ is primarily responsible for proteoglycan cleavage in these
experimental systems and that this protease has properties in common with metalloproteases including members of
the MMP and ADAM family. Inhibition of ‘aggrecanase’ may have utility in preventing cartilage loss in arthritis.
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Introduction
In arthritic conditions there is a loss of cartilage
matrix components which in normal joints provide
cartilage with its mechanical properties of reduc-
ing load during joint articulation. One of the
earliest changes observed in cartilage morphology
is depletion of proteoglycan (aggrecan) [1] which,
due to its high negative charge and water-binding
capacity, provides cartilage with its properties of
compressibility and resilience. This loss appears to
be due to an increased rate of aggrecan degra-
dation which can be attributed to proteolytic
cleavage within the interglobular domain (IGD)
located between the G1 and G2 globular domains
of aggrecan. Several matrix metalloproteinases
(MMPs), synthesized and secreted by connective
tissue cells, have been shown to cleave aggrecan in
this IGD region at a specific site between amino
acid residues Asn 341–Phe342 [2, 3] and G1 fragments
with this cleavage site have been identified within
articular cartilage bound to hyaluronic acid [4].
However, C-terminal fragments with the new
N-terminus, ARGSVIL . . ., formed by cleavage
between the amino acid residues Glu373–Ala374 have
been identified in synovial fluid of patients with
osteoarthritis [5], inflammatory joint disease [6]
and in the media from cartilage explant and
chondroctye cultures stimulated with interleukin-
1 or retinoic acid [2, 7–10], suggesting that
cleavage at this site may also play an important
role in cartilage degradation.
Many matrix metalloproteinases (MMP-1, -2, -3,
-7, -8, -9 and -13) have been shown to cleave
aggrecan in vitro at the Asn341–Phe342 site [3, 4, 11–
12]. In contrast, attempts to generate cleavage at
the Glu373–Ala374 site with a number of purified
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proteinases have been less successful [3, 4, 13].
Therefore, this cleavage is thought to be the result
of a novel, as yet unidentified proteinase, given the
name ‘aggrecanase’ based on its ability to cleave
the aggrecan core protein. However, recent in vitro
studies, using a purified G1–G2 substrate or native
bovine cartilage aggrecan substrate, demonstrated
the ability of native and recombinant neutrophil
collagenase (MMP-8) to cleave at the Glu373–Ala374
‘aggrecanase’ site, although the preferential cleav-
age site was the Asn341–Phe342 bond [14, 15] and
articular chondrocytes have been shown to be
capable of synthesizing MMP-8 [16]. These data
demonstrate that an MMP can cleave at this site
under specific conditions and open the possibility
that the cartilage ‘aggrecanase’ may be a matrix
metalloproteinase.
In the studies reported herein, we use an
antibody, BC-3, which specifically recognizes the
new N-terminus, ARGSVIL, generated by cleavage
of aggrecan at the Glu373–Ala374 ‘aggrecanase’ site
[17] to follow the generation of proteoglycan
catabolites produced by cleavage at this site in
response to cytokines in explant cultures of both
bovine nasal and bovine articular cartilage
cultures and also the ability of inhibitors to block
this cleavage. These studies indicate that a variety
of anti-arthritic compounds which are ineffective
in blocking cleavage at the ‘aggrecanase’ site do
not block proteoglycan release from the tissue in
response to interleukin-1 (IL-1) stimulation of
cartilage in culture. In contrast, we show that two
compounds which broadly inhibit MMP activity by
different mechanisms (an active-site MMP inhibi-
tor and an inhibitor of activation of the MMP
zymogens), block specific cleavage at the ‘aggre-
canase’ site and the release of cartilage aggrecan
catabolites. The data reported herein suggest that
‘aggrecanase’ is primarily responsible for proteo-
glycan cleavage in these experimental systems and
that this protease may be activated by or have
properties in common with metalloproteases
including members of the MMP and ADAMD
(a disintegrin and metalloprotease domain) family
of proteases.
Materials and Methods
materials
Dulbecco’s modified Eagle’s medium (DMEM),
fetal calf serum, penicillin/streptomycin/
amphotericin B, and neomycin were from Gibco
(Grand Island, NY, U.S.A.). The IL-1 used was a
soluble, fully-active recombinant human IL-1b
produced as described previously [18]. The specific
biological activity was 1 · 107 units/mg of protein,
with 1 unit being defined as the amount of IL-1 that
generated half-maximal activity in the thymocyte
proliferation assay. Keratanase, keratanase II and
chondroitinase ABC were from Seikuguku (Kogyo,
Japan). Monoclonal antibody BC-3 was prepared
as ascitic fluid and was shown to be specific for the
amino acid sequence ARGSVI . . . at the
N-terminus of aggrecan fragments [17, 19]. Western
blot detection used the Promega AP system from
Promega (Madison, WI, U.S.A.). The hydroxamic
acid active-site proMMP inhibitor, BB-16 ((2S,
3R)-2-methyl-3-(2-methylpropyl)-1-(N-hydroxy)-4-
(o-methyl)-L-tyrosine-N-methyl amide) and the
isothiazolone inhibitor of proMMP activation,
XG076 (7-aza-2-phenylbenzisothiazol-3-one), were
syn-
thesized at DuPont Merck as previously described
[20, 21]. Indomethacin, naproxen, tenidap,
doxycycline and dexamethasone were from Sigma
(St. Louis, MO, U.S.A.). All other reagents used
were of analytical grade.
tissue preparation
Bovine nasal septa were obtained fresh at the
time of slaughter. Uniform cartilage discs (1 mm
thick, 8 mm in diameter, 080 mg) were prepared
under sterile conditions as described by Steinberg
et al. [22]. Bovine articular cartilage was obtained
from the metacarpophangeal joints of 2–3-year-old
cows. Cartilage was allowed to equilibrate for at
least 3 days in culture with DMEM supplemented
with 5% heat-inactivated fetal calf serum,
penicillin, streptomycin, amphotericin B, and
neomycin (100 IU/ml, 100 mg/ml, 0.25 mg/ml and
50 mg/ml, respectively) prior to treatment as
described below.
organ culture
Cartilage pieces were cultured as described
previously [23]. For bovine nasal cartilage, discs
were either weighed and incubated two per well in
a 12-well culture dish with 1 ml media or were cut
into eighths and each eighth of a cartilage disc was
weighed, then placed into a well of a 96-well
culture dish containing 180 ml of serum-free
DMEM containing penicillin, streptomycin,
amphotericin B, and neomycin (100 IU/ml,
100 mg/ml, 0.25 mg/ml and 50 mg/ml, respectively).
Paired explants from the same disc were used to
compare the effects of various inhibitor
treatments. Bovine articular cartilage slices were
cut into pieces of approximately 10 mg, weighed
and cultured as described for nasal cartilage. Eight
replicates per treatment group were run for each
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experiment. Cultures were incubated at 37° C in an
atmosphere of 95% air/5% CO2.
inhibitor studies
Compounds were dissolved in DMSO (10 - 2 m)
and further diluted with DMEM, supplemented
with antibiotics, to the required concentrations.
DMSO concentrations in the culture media never
exceeded 1%; this concentration of DMSO had no
effect on alterations in cartilage proteoglycan
metabolism in response to IL-1. Cartilage was
incubated in the absence or presence of IL-1
(10–50 ng/ml) with or without inhibitor for 48 h.
For timecourse studies, cultures were incubated in
the absence or presence of IL-1 with or without
inhibitor for time periods up to 72 h. For
cycloheximide studies, cultures were incubated in
control media or in IL-1 (50 ng/ml) with and
without cycloheximide (5 mg/ml). At the end of the
incubation, media and cartilage slices were
harvested and frozen for further analysis. For
proteoglycan synthesis studies, at the end of the
incubation, the media were replaced with Ham’s
F-12 media, containing 20 mCi/ml of [35S]-sulfate
and cultures were incubated for a 2-h labeling
period and assayed for incorporation as previously
described [23]. Briefly, the media were then
removed, the cartilage was digested overnight with
papain, the proteoglycan in the digest precipitated
with cetylpyridinium chloride, and the precipitates
counted for 35S on a Packard Matrix 96 counter.
[35S]sulfate incorporation was determined as
disintegrations per minute (dpm) per milligram of
wet weight cartilage.
extraction and purification of aggrecan and
aggrecan catabolites
Bovine nasal cartilage slices were sectioned
(0.2 mm) and then the proteoglycans were extracted
for 48–72 h at 4° C with 4 m guanidinium
hydrochloride, 50 mm sodium acetate buffer,
pH 6.8, containing the proteinase inhibitors
disodium EDTA, 6-aminohexanoic acid,
benzamidine hydrochloride and phenyl-
methanesulfonyl fluoride. Aggrecan was further
purified on a CsCl density gradient under
dissociative conditions [24].
glycosaminoglycan assay
Glycosaminoglycan (GAG) levels in the culture
media or cartilage were determined by the the
amount of polyanionic material reacting with
1,9-dimethylmethylene blue [25], using shark
chondroitin sulfate as a standard. Results were
reported as micrograms of GAG per milligram of
wet weight cartilage or as percent total GAG
released.
deglycosylation of aggrecan and aggrecan
catabolites
Proteoglycans and proteoglycan metabolites
from media or cartilage were digested with
chondroitinase ABC (0.01–0.1 units/10 mg GAG),
keratanase (0.01–0.1 units/10 mg GAG and
keratanase II (0.001–0.002 units/10 mg GAG) in
buffer containing 50 mm sodium acetate, 0.1 m
Tris-HCl, pH 6.5, at 37° C for 2 h or overnight
at 4° C [17]. The digests were monitored by
measuring the decrease in GAG content. After
digestion, the samples were either dialyzed
exhaustively against dH2O and dried using a
speed vac or the proteoglycans were precipitated
with five volumes of acetone and reconstituted
in an appropriate volume of SDS-PAGE sample
buffer.
analysis of aggrecan catabolites
Aggrecan catabolites were analyzed by sodium
dodecyl sulfate polyacrylamide gel electrophoresis
(SDS/PAGE) under non-reducing conditions on
4–12% or 4–15% gradient polyacrylamide gels [26],
followed by electroblotting onto nitrocellulose
membranes. The membranes were probed with
monoclonal antibody BC-3 (which recognizes the
new N-terminal neoepitope 373ARGSVI . . .
generated by cleavage of the aggrecan core protein
by the unknown enzyme activity ‘aggrecanase’)
[17] at a dilution of 1:1000. The BC-3 antibody has
been shown to specific for this sequence of amino
acids at the N-teminus of aggrecan fragments and
does not recognize this same sequence when
present within the peptide spanning the cleavage
site [17, 19]. Subsequently, membranes were
incubated with an alkaline phosphatase-
conjugated goat anti-mouse IgG and aggrecan
catabolites visualized by incubation with the
appropriate substrate for 10–30 min to achieve
maximal signal intensity [27]. Sum density of all
BC-3-reactive aggrecan fragments were then
quantified by scanning densitometry using a UVP
Image Store 7500 system (UVP, Upland, CA,
U.S.A.) and IP Lab Gel software (Signal Analysis
Corporation, Vienna, VA, U.S.A.) for density
analysis and quantitation. Overnight transfer
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resulted in complete transfer of low and high
molecular weight standards and the densitometric
response was found to be linear over
the density range required for the blots, as
determined by loading increasing amounts of
BC-3-reactive material.
statistical analysis
Significant differences in GAG release between
groups were tested by Duncan’s multiple range
test when analysis of variance was significant
(P Q 0.05). Values are shown as mean 2 s.e.m.
The r2 value for GAG release versus BC-3
epitope generation in response to IL-1 or TNF was
determined by regression analysis.
Results
analysis of proteoglycan catabolites from
bovine nasal cartilage exposed to either
il-1bor tnfa
Media samples containing aggrecan catabolites
from bovine nasal cartilage exposed to either IL-1b
(Fig. 1) or tumour necrosis factor (TNF) (Fig. 2)
were subjected to SDS/PAGE (4–12%) and Western
blot analysis with monoclonal antibody BC-3 that
specifically recognizes the N-terminal neoepitope
sequence ARGSVI . . . on aggrecan catabolites
[Figs 1(a) and 2(a)] or analyzed for the release of
proteoglycan metabolites by monitoring sulfated
GAG using the dimethylmethylene blue assay
[Figs 1(b) and 2(b)]. Western blot analysis
Fig. 1. IL-1 stimulation of bovine nasal cartilage
aggrecan degradation. Bovine nasal cartilage was
incubated in control media or in media containing
varying concentrations of IL-1 (0.1–1000 ng/ml). At the
end of the culture period, media were analyzed for (a)
aggrecan fragments containing the N-terminus,
ARGSVIL, by BC-3 Western blot analysis on 4–12% gels
with loading on an equal GAG basis (20 mg/lane) or (b)
for sulfated GAG concentrations by the dimethyl-
methylene blue dye assay.
Fig. 2. TNF stimulation of bovine nasal cartilage
aggrecan degradation. Bovine nasal cartilage was
incubated in control media or in media containing
varying concentrations of TNF (1–10 000 ng/ml). At the
end of the culture period, media were analyzed for (a)
aggrecan fragments containing the N-terminus,
ARGSVIL, by BC-3 Western blot analysis on 4–12% gels
with loading on an equal GAG basis (20 mg/lane) or (b)
for sulfated GAG concentrations by the dimethyl-
methylene blue dye assay.
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indicated that exposure to IL-1b at a concentration
of 10 ng/ml was sufficient to generate the release of
BC-3-positive aggrecan degradation products into
the media of the explant cultures [Fig. 1(a)]. In
contrast, the minimum concentration of TNF
required to generate aggrecan metabolites with the
BC-3 epitope [Fig. 2(a)] was found to be 10-times
that of the observed IL-1b concentration
(100 ng/ml vs 10 ng/ml, respectively). No
‘aggrecanase’-generated product was evident
in control cultures, without cytokine, or at
cytokine concentrations which did not induce
GAG release [Fig. 1(b) and 2(b)]. Densitometric
analysis of the immunopositive staining for BC-3
and calculation of BC-3 epitope released (measured
as arbitrary units of epitope/ml), at each
concentration of IL-1b or TNF, demonstrated that
there was a concentration-dependent increase in
‘aggrecanase’ activity with both cytokines.
Comparison of these data with total proteoglycan
metabolites (measured as micrograms of GAG
per milliliter) (Fig. 3) indicated a significant
positive correlation (r2 = 0.99 and P = 0.0001)
between GAG released into the media and
‘aggrecanase’-mediated fragment generation
which suggests, but does not prove, a commonality
of their origin.
Fig. 4. Timecourse of the release of aggrecan catabolites
from control and IL-1 stimulated bovine nasal cartilage.
Bovine nasal cartilage slices were cultured in the
presence (R) or absence (W) of 50 ng/ml IL-1 for different
time periods. At the end of the culture period, the media
and cartilage slices were analyzed for GAG content by
the dimethylmethylene blue dye assay and the percent-
age of GAG released was plotted vs time (a). To
determine ‘aggrecanase’-generated cleavage, media were
evaluated for fragments containing the N-terminus,
ARGSVIL, by BC-3 Western analysis on 4–15% gels with
loading on an equal GAG basis (20 mg/lane) (b).
Fig. 3. Correlation between IL-1- and TNFa-induced
generation of BC-3 reactive aggrecan fragments and
GAG release from bovine nasal cartilage. Sum density of
all BC-3 reactive bands was quantitated by scanning
densitometry for each treatment and BC-3 epitope
contentration per milliliter of media plotted versus GAG
concentration per milliliter from the experiments in Fig.
1 and 2 and the r2 value determined by regression
analysis.
time course of the generation of aggrecan
catabolites from control and il-1b treated
bovine explant cultures
Bovine nasal and bovine articular cartilage
slices were cultured in the presence or absence of
IL-1b (50 ng/ml) for different time periods over 48 h.
Analysis of the release of proteoglycan metabolites
into the media by GAG analysis showed that there
was a difference in the percent release of total
glycosaminoglycan from the bovine nasal
compared to articular cartilage slices that were
treated with a single dose of IL-1b [Figs 4(a) and
5(a)]. At 48 h the percentage of GAG released from
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IL-1-treated bovine nasal cartilage was 72%
compared to 8% release in control cultures or a
ninefold increase, whilst in bovine articular
cartilage there was 15% GAG released in
IL-1-treated cultures, compared with 2% release in
control cultures, or approximately an eightfold
increase. Thus, although there was a difference in
total percent GAG released in nasal vs articular
cartilage, the fold increases were similar.
BC-3 Western blot analysis of media detected
‘aggrecanase’-generated fragments from 8 to 48 h
in IL-1b cultures of nasal cartilage [Fig. 4(b)] and
articular cartilage [Fig. 5(b)]; no immunoreactive
bands were detected at earlier timeperiods. A
weak BC-3 positive immunostaining was seen in
control bovine articular cartiage cultures;
Fig. 6. Effect of cycloheximide on ‘aggrecanase’-gener-
ated fragments produced in response to IL-1. Bovine
nasal cartilage was incubated for 48 h in control media
(lane 1) or 50 ng/ml IL-1 in the absence (lane 2) or
presence (lane 3) of cycloheximide. At the end of the
culture period, media were analyzed for aggrecan
fragments containing the N-terminus, ARGSVIL, by
BC-3 Western blot analysis on 4–12% gels with loading
on an equal GAG basis (20 mg/lane).
Fig. 5. Timecourse of the release of aggrecan catabolites
from control and IL-1 stimulated bovine articular
cartilage. Bovine articular cartilage slices were cultured
in the presence (R) or absence (W) of 50 ng/ml IL-1 for
different time periods. At the end of the culture period,
the media and cartilage slices were analyzed for GAG
content by the dimethylmethylene blue dye assay and
the percentage of GAG released was plotted vs time (a).
To determine ‘aggrecanase’-generated cleavage, media
were evaluated for fragments containing the N-termi-
nus, ARGSVIL, by BC-3 Western analysis on 4–15% gels
with loading on an equal GAG basis (20 mg/lane) (b).
however, this was much less than that seen in the
IL-1b treated cultures. In bovine nasal cartilage
control cultures this was only weakly discernible
at 24–48 h [Fig. 4(b)]. Loading of blots in these
experiments was done on an equal GAG basis and
essentially equal amounts of total epitope per GAG
were detected from IL-1-stimulated cultures
between 8–48 h. In other words, the time-dependent
increase in GAG concentration was accompanied
by an equivalent increase in the concentration of
BC-3 reactivity. On the other hand, the BC-3
epitope per GAG in control samples was very low
or undetectable in most cases.
A BC-3 positive band migrating at 080 kDa was
seen in the IL-1-stimulated cultures in this
experiment which was absent in media from
experiments shown in Fig. 1 and 2, and a band at
050 kDa varied in intensity in different samples in
this experiment. These differences may represent
animal to animal variations in GAG substitution,
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and thereby susceptibility of C-terminal
‘aggrecanase’ sites to cleavage, due to age or other
factors.
analysis of media from explant cultures
treated with and without il-1b, and with il-1b
in the presence of cycloheximide
Bovine nasal cartilage slices were cultured
in the presence of IL-1b and cycloheximide for
48 h to investigate the requirement of de novo
protein synthesis for the generation of
‘aggrecanase’ activity. Western blot analysis of
aggrecan degradation products released into
the medium of the explant cultures treated
with IL-1b identified the expected BC-3
immunopositive bands (Fig. 6, lane 2). In
contrast, the presence of ‘aggrecanase’-generated
(BC-3-positive) proteoglycan catabolites was
not observed in explant cultures containing IL-1b
plus cycloheximide or in control cultures
(Fig. 6, lanes 3 and 1, respectively). This
result indicates that de novo protein synthesis is
required for ‘aggrecanase’-mediated cleavage to
occur.
effectofanti-arthritic drugson ‘aggrecanase’-
mediated cleavage of aggrecan in cartilage
explant cultures exposed to il-1
We investigated the ability of a variety of
anti-arthritic compounds with differing
mechanisms of action to inhibit specific cleavage
of aggrecan at the Glu373–Ala374 ‘aggrecanase’ site
in an IL-1-stimulated bovine nasal cartilage organ
culture system following a 48 h incubation
[Fig. 7(a)]. Media from control cultures did not
exhibit any detectable BC-3-reactive fragments,
whereas media from cartilage incubated with IL-1
(50 ng/ml) showed intense bands representing
fragments generated by cleavage at the
‘aggrecanase’ site. Inclusion of indomethacin,
tenidap, naproxen or doxycycline at 10 mm or
dexamethasone at 1 mm did not inhibit the
generation of BC-3-reactive fragments in response
to IL-1. This lack of inhibition of
‘aggrecanase’-mediated cleavage was reflected in a
lack of significant inhibition of aggrecan
degradation by these compounds as monitored by
release of GAG from the cartilage into the culture
media [Fig. 7(b)]. Although there appears to be
somewhat less GAG release in the presence of
tenidap and somewhat more in the presence of
doxycycline, these differences were not
statistically significant and this is consistent with
results seen in previous studies examining
their effects on IL-1-stimulated GAG release [28, 29
and E.C. Arner and M. A. Pratta, unpublished
data].
inhibition of ‘aggrecanase’ cleavage by an
active-site matrix metalloproteinase inhibitor,
bb-16
In order to determine whether inhibitors of
MMP activity would block ‘aggrecanase’-mediated
Fig. 7. Effect of anti-arthritic drugs on cartilage
aggrecan degradation. Bovine nasal cartilage was
incubated for 48 h in control media or 50 ng/ml of IL-1 in
the absence or presence of drug (1 = 10 mm indomethacin;
2 = 10 mm tenidap; 3 = 10 mm naproxen; 4 = 10 mm doxycy-
cline; 5 = 1 mm dexamethasone). At the end of the culture
period, media were analyzed for aggrecan fragments
containing the N-terminus, ARGSVIL, by BC-3 Western
blot analysis on 4–12% gels with loading on an equal
volume basis (a) and for total aggrecan degradation by
measuring the glycosaminoglycan (GAG) released per
milligram of cartilage wet weight (b).
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Fig. 8. Inhibition of ‘aggrecanase’-mediated cleavage by
the hydroxamate matrix metalloproteinase inhibitor
BB-16. Bovine nasal cartilage was incubated for 48 h in
control media or 50 ng/ml of IL-1 in the absence or
presence of BB-16. At the end of the culture period media
were analyzed for aggrecan fragments containing the
N-terminus, ARGSVIL, by BC-3 Western analysis on
4–12% gels with loading on an equal volume basis (a)
and for aggrecan breakdown by measuring the gly-
cosaminoglycan (GAG) released per milligram of
cartilage wet weight (b). Percent inhibition of IL-1-
stimulated BC-3 epitope generation (Q) and GAG
release (W) were plotted vs inhibitor concentration (c) to
determine IC50 values.
cleavage in cartilage explants, we used the
peptidic hydroxamate, BB-16 [20], which is a
potent, broad inhibitor of MMPs (MMP-3
Ki = 1.0 nm; MMP-1 Ki = 0.05 nm; MMP-8
Ki = 0.7 nm). Western blot analysis using
monoclonal antibody BC-3 [Fig. 8(a)] showed that
inclusion of BB-16 during IL-1-stimulated cartilage
degradation resulted in a concentration-dependent
inhibition of the generation of BC-3-reactive
fragments. This inhibition of specific cleavage at
the ‘aggrecanase’ site was reflected in a
concentration-dependent decrease in GAG release
[Fig. 8(b)] as monitored by dimethylmethylene blue
dye assay of the culture media. Significantly, both
BC-3 fragment generation and GAG release were
inhibited by greater than 90% with this inhibitor.
Although 30–100 mm BB-16 was required to achieve
complete inhibition of GAG release, no effect on
proteoglycan synthesis was seen at concentrations
up to 100 mm (control = 3678 2 315 dpm/mg;
IL-1 = 577 2 74 dpm/mg; IL-1 + BB-16 (100 mm) =
540 2 69 dpm/mg), indicating that inhibition was
not due to a cytotoxic effect on chondrocytes or to
interference with IL-1 signalling. The amount of
compound required to cause half-maximal
inhibition (IC50) of GAG release was estimated
from the concentration–response curve to be 6.3 mm
and the IC50 for inhibition of specific cleavage at
the ‘aggrecanase’ site was estimated to be 2.0 mm
[Fig. 8(c)]. The similar IC50s for inhibition
of GAG release and inhibition of specific
‘aggrecanase’-mediated proteolysis are consistent
with cleavage at the Glu373–Ala374 bond
representing the primary proteolytic event in the
catabolism of aggrecan in this explant system.
timecourse of il-1-induced cleavage in the
absence and presence of bb-16
The timecourse of IL-1-induced aggrecan
cleavage was investigated in the absence and
presence of the MMP inhibitor, BB-16. Evaluation
of specific cleavage at the Glu373–Ala374
‘aggrecanase’ site by BC-3 Western blot analysis
[Fig. 9(a)] showed an increase in the fragments
formed by cleavage at this site with time in both
the absence and presence of BB-16 with the rate of
cleavage decreased in the presence of BB-16.
Complete inhibition of BC-3 reactive fragment
generation was achieved at 16 h with 30 mm BB-16.
Although in the presence of inhibitor a faint band
was detectable by 24 h which increased by 48 and
72 h, significant inhibition (81%) was maintained
through 72 h. Fig. 9(b) shows that cummulative
GAG release from the cartilage increased in a
time-dependent manner in both the absence and
72
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Fig. 9. Timecourse of IL-1-induced aggrecan cleavage in the absence and presence of BB-16. Bovine nasal cartilage
was incubated in IL-1 (10 ng/ml) in the absence (W) or presence (Q) of 30 mm BB-16 for various times. The media were
then analyzed for BC-3 fragment generation by BC-3 Western blot analysis on 4–15% gels with loading on an equal
GAG basis (a) and for GAG released into the media per milligram wet weight cartilage (b).
presence of inhibitor; however, the rate of release
was significantly lower in the presence of
BB-16.
inhibition of aggrecan cleavage by an inhibitor
of pro-mmp activation
To determine whether interferring with normal
MMP zymogen activation would also result in
inhibition of ‘aggrecanase’-mediated cleavage, the
isothiazolone, XG076, which interfers with
activation of proMMPs [30] was included with IL-1
during culture. XG076 caused a concentration-
dependent inhibition of specific cleavage at the
‘aggrecanase’ site as measured by BC-3 Western
blot analysis [Fig. 10(a)]. This again corresponded
with inhibition of total aggrecan degradation as
monitored by GAG release from the cartilage
[Fig. 10(b)]. The IC50s for inhibition of GAG release
and BC-3 fragment generation were estimated from
the concentration–response curves [Fig. 10(c)] to
be 3.0 mm and 0.5 mm, respectively. As was found
with BB-16, the IC50s are similar, again suggesting
that cleavage at the ‘aggrecanase’ site is the
primary proteolytic event in the catabolism of
aggrecan in this explant system.
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Fig. 10. Inhibition of aggrecan degradation by an
inhibitor of matrix metalloproteinase activation. Bovine
nasal cartilage was incubated for 48 h in control media
or 10 ng/ml of IL-1 in the absence or presence of the
isothiazolone, XG076. At the end of the culture period,
media were analyzed for aggrecan fragments containing
the N-terminus, ARGSVIL, by BC-3 Western analysis on
4–12% gels with loading on an equal volume basis (a)
and for aggrecan breakdown by measuring the gly-
cosaminoglycan (GAG) released per milligram of
cartilage wet weight (b). Percent inhibition of IL-1-
stimulated BC-3 epitope generation (Q) and GAG
release (W) were plotted versus inhibitor concentration
(c) to determine IC50 values.
Discussion
We have demonstrated that proteoglycan
degradation in bovine cartilage in response to
either IL-1 or TNF stimulation is associated with
the release of aggrecan fragments generated by
cleavage at the Glu373–Ala374 ‘aggrecanase’ site.
Cleavage at this site is observed during stimulated
proteoglycan catabolism in articular as well as
nasal cartilage. There was both a temporal and
concentration-related association between the
appearance of BC-3 immunoreactive fragments
(indicating specific cleavage at the ‘aggrecanase’
site) and the release of GAG from cartilage (as a
measure of total proteoglycan degradation). The
strong positive correlation which we observed
between GAG release and specific cleavage at the
‘aggrecanase’ site in concentration–response
studies with IL-1 or TNF suggests that the
degradation of aggrecan in response to these
cytokines is associated with cleavage by
‘aggrecanase’.
Although we have found that MMP production
is stimulated in response to IL-1 and TNF in these
cultures, including proMMP-1, -2, -3, and -9 (E. C.
Arner and M. D. Tortorella, unpublished
observations), Western blot analyses using
antibody BC-14 (which recognizes the catabolic
neoepitope FFGVG . . . on aggrecan catabolites
produced by proteolysis of the interglobular
domain of aggrecan with MMPs) were negative
(data not shown), thus suggesting that the
aggrecan catabolites were not generated through
the action of MMPs. Our data are consistent with
studies in rat chondrosarcoma cell lines and
primary bovine chondrocytes stimulated with
retinoic acid or IL-1, where aggrecan catabolic
products contained a single N-terminal sequence
initiating at Ala374 and a single G1 fragment with
the C-terminus Glu373 indicating that aggrecan
catabolism in these systems primarily involves
cleavage at the Glu373–Ala374 bond by ‘aggrecanase’
[10].
The work of Lark et al. [31] demonstrate that
both ‘aggrecanase’ and MMP activities are
involved in cleavage of aggrecan in normal and
arthritic human cartilage. However, as the
authors point out, since these studies evaluated
N-terminal aggrecan cleavage fragments
remaining within the cartilage, they only show
that cleavage at both sites had occurred, but do not
provide any information on the relative
contribution of these two activities or whether the
fragments present were generated during normal
turnover or during the arthritic process. Clearly in
the current studies where aggressive degradation
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of cartilage aggrecan is induced by IL-1,
‘aggrecanase’-mediated cleavage appears to
predominate.
Furthermore, we have demonstrated that
specific cleavage of aggrecan at the Glu373–Ala374
‘aggrecanase’ site is blocked by MMP inhibitors.
This inhibition is concentration related and
corresponds with inhibition of aggrecan
catabolism as monitored by release of GAG from
the cartilage. Similar IC50s obtained with BB-16 for
inhibition of GAG release and inhibition of the
generation of fragments containing the new
N-terminus ARGSVIL, produced by ‘aggrecanase’-
mediated proteolysis, are consistent with cleavage
at the Glu373–Ala374 bond representing the primary
proteolytic event in the catabolism of aggrecan.
The possibility that there is a slight difference in
sensitivity of GAG release and BC-3 fragment
generation to the inhibitors tested could not be
ruled out. This could potentially be due to cleavage
by ‘aggrecanase’ within the C-terminal region of
aggrecan, where three additional ‘aggrecanase’
sites have been proposed [32], that would not be
detected with the BC-3 antibody.
Although the tissue content of BC-3 was not
evaluated in these studies to confirm that
fragments containing this epitope are eluting out
of the cartilage as would be expected, in ongoing
studies, data on cartilage extracts indicate that
there is no buildup of BC-3 reactive fragments
within the cartilage of inhibitor-treated cultures,
but rather that these fragments are not produced
in the presence of inhibitor (E. C. Arner and M. A.
Pratta, unpublished data).
The data reported herein for inhibition with
BB-16 are supported by studies demonstrating a
significant positive correlation (r2 = 0.84;
P = 0.0001) between percent inhibition of GAG
release and percent inhibition of BC-3-reactive
fragment generation for a series of MMP inhibitors
(E. C. Arner, C. P. Decicco and M. D. Tortorella,
unpublished data). Consistent with this suggestion
is the strong positive correlation that we observed
between GAG release and specific cleavage at the
‘aggrecanase’ site in response to IL-1b or TNFa
stimulation of bovine nasal cartilage.
In contrast, three different nonsteroidal
anti-inflammatory drugs, indomethacin, tenidap
and naproxen, were ineffective in blocking
generation of BC-3-reactive fragments as were the
steroid, dexamethasone, and the tetracycline
analog, doxycycline. The compounds used in these
experiments were previously tested in
concentration–response studies for their ability to
inhibit GAG release from bovine nasal cartilage in
response to IL-1 [28, 29, and E. C. Arner and M. A.
Pratta, unpublished observations] and shown to be
ineffective over a range of concentrations. The
concentrations used in this study were generally
chosen to be the highest concentration which did
not cause a decrease in proteoglycan synthesis.
Our goal in the current studies was to determine
whether any of these compounds which do not
block GAG release from cartilage would, in
contrast, result in an inhibition of cleavage at the
‘aggrecanase’ site. If this were the case, it might
suggest that cleavage by ‘aggrecanase’ is not
critical for proteoglycan degradation. However,
none of these compounds affected specific cleavage
at the ‘aggrecanase’ site as detected by BC-3
Western analysis. These results are consistent with
the hypothesis that release of GAG is correlated
with aggrecanase-mediated cleavage.
The nonsteroidal anti-inflammatory drugs,
indomethacin and naproxen, have been reported
by a number of investigators to have either no
effect or to negatively effect aggrecan catabolism
in vitro [28, 29, 33–39]. Although there are some
reports of naproxen inhibiting cartilage
proteoglycan breakdown [40, 41], neither
indomethacin nor naproxen have been shown to be
effective clinically in blocking cartilage
degradation [42].
Tenidap has been reported to be capable of
blocking cartilage degradation via several
mechanisms including inhibition of IL-1
production, inhibition of MMP synthesis and
activity, and reduction of IL-1 receptor levels
[43–46]. However, in the current studies no
significant inhibition of aggrecan loss was
observed with 10 mm tenidap, and this correlated
with a lack of inhibition of specific cleavage at the
‘aggrecanase’ site. Interestingly, however, the
tenidap-treated cultures which showed a
nonsignificant 31% inhibition of GAG release, also
showed a 28% decrease in BC-3 sum density. When
the concentration of tenidap was increased to
100 mm, decreased loss of GAG was achieved;
however, this was paralleled by a significant
inhibition of aggrecan synthesis (E. C. Arner,
unpublished data). Since tenidap has been
reported to decrease chondrocyte cell viability and
decrease DNA content in chondrocyte cultures [47]
at similar concentrations, this suppression of
aggrecan synthesis suggests that a general
cytotoxic effect of tenidap may be responsible for
the decrease in aggrecan catabolism at these high
drug concentrations in our studies.
Tetracyclines have been reported to inhibit
MMP-1, -8, and -9, but not MMP-3 [48–50] and thus
may be more limited inhibitors, not providing
broad inhibition of the entire MMP family. The
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lack of inhibition of BC-3-reactive fragment
generation by the tetracycline analog,
doxycycline, suggests that these compounds are
not effective against ‘aggrecanase’-mediated
cartilage degradation. Dexamethasone was also
ineffective in blocking specific cleavage at the
‘aggrecanase’ site or general aggrecan degradation
as monitored by GAG release. These results are
consistent with the lack of clinical efficacy of
steroids in preventing cartilage loss in man.
Timecourse studies demonstrated that
BC-3-reactive aggrecan catabolites were not
detectable in the media or cartilage until 8 h of
stimulation with 50 ng/ml IL-1 or 16 h of
stimulation with 10 ng/ml IL-1, indicating that
time is required for the generation of
‘aggrecanase’-mediated cleavage. This observation
together with the cycloheximide data indicates
that the degradative mechanisms leading to the
induction of ‘aggrecanase’ activity in cartilage
requires de novo protein synthesis.
BC-3 reactive bands were generally not
detectable in media from control cultures with
equal loading on a GAG basis, indicating that
aggrecanase is not responsible for proteoglycan
release under unstimulated conditions.
Interestingly, in the timecourse studies carried out
in the absence and presence of BB-16 (Fig. 9),
although samples were loaded on an equal GAG
basis, different amounts of BC-3 epitope were
observed in the 16 and 24 h as compared with the
48 and 72 h cultures. This indicates that the BC-3
epitope per GAG is different for the early versus
later timepoints, suggesting that at the early times
a lower proportion of the released GAG-containing
fragments had been cleaved at the ‘aggrecanase’
site. Therefore, it is likely that at the early
timeperiods, when a low amount of stimulated
GAG release (over that seen in control cultures) is
observed, only a small portion of the GAG release
is due to ‘aggrecanase’, while the remainder occurs
via the mechanism responsible for unstimulated
turnover. At later timepoints, the majority of the
GAG release would be due to stimulated
degradation, which our data indicates is
‘aggrecanase’ mediated. A lower amount of BC-3
epitope per GAG was also seen in the
inhibitor-treated cultures. This is to be expected if
the compound is inhibiting the ‘aggrecanase’
activity responsible for stimulated degradation,
but not effecting the factor responsible for control
release.
Although MMP-1, -2, -3, -7, -8, -9, and -13 all
cleave at the Asn341–Phe342 bond on incubation with
aggrecan in solution [3, 4, 11, 12], the report that
the Glu373–Ala374 bond can be cleaved by incubation
with high concentrations of MMP-8 [14] opened
the possibility that ‘aggrecanase’ might be a new
member of the MMP family which may directly
degrade aggrecan at the Glu373–Ala374 bond or be
part of a proteolytic cascade which results in this
cleavage. The data presented herein showing that
cleavage at the Glu373–Ala374 bond in response to
IL-1 stimulation can be inhibited by a hydroxamate
active-site inhibitor with a broad range of
selectivity within the MMP family is consistent
with this hypothesis.
We have also demonstrated inhibition of
‘aggrecanase’-mediated cleavage by an
isothiazalone compound that acts through a
completely different mechanism to inhibit MMPs
by interfering with the activation of the latent
MMP zymogen [30]. XG076 has no effect on
proteoglycan synthesis in control cartilage
cultures or on protein synthesis in chondrocyte
cultures (unpublished data) and does not abrogate
the inhibition of proteoglycan synthesis in
response to IL-1 [30] indicating that it does not
interfere with IL-1 signalling, thus supporting the
contention that this compound is specifically
inhibiting the activation of a pro-MMP in this
system. Data with this inhibitor provides further
support to suggest that an enzyme with
characteristics in common with the known MMPs
is involved in degradation of proteoglycan at the
‘aggrecanase’ site.
We have recently demonstrated that BB-16 is
also capable of inhibiting the proteolytic activity
of soluble active ‘aggrecanase’ in conditioned
media from IL-1-stimulated bovine nasal cartilage
cultures [51]. In contrast, not all MMP inhibitors
are effective in blocking ‘aggrecanase’ activity.
Although BB-16 is ineffective against serine,
cysteine or aspartyl proteases (E.C. Arner,
unpublished data), hydroxamates have been shown
to inhibit other related metalloproteases, such as
those of the ADAMs (a disintegrin and
metalloprotease domain) family, like TNF
convertase [52, 53]. Thus, although inhibition by
BB-16 supports the possibility that ‘aggrecanase’
may be a member of the MMP family, it does not
rule out the alternative possibility that
‘aggrecanase’ may be a member of a related family
of metalloproteases.
The Ki’s for the active-site inhibitor, BB-16,
against MMP-1, -3, and -8 in enzymatic assays
using a peptide substrate, are in the nanomolar
range while the IC50 for inhibition of GAG release
and specific ‘aggrecanase’-mediated cleavage at
the Glu373–Ala374 bond are in the micromolar range,
suggesting that none of these known MMPs
represent ‘aggrecanase’. However, the possibility
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exists that these differences may reflect differences
in substrate concentration or presentation within
the cartilage matrix. Interestingly, the IC50 for
inhibition of normal pro-MMP activation by the
isothiazolone, XG076, using proMMP-3 as a model
matrix metalloproteinase zymogen, is in the
micromolar range (E. C. Arner and M. D
Tortorella, unpublished data) similar to the value
for inhibition of cartilage aggrecan cleavage.
MMP-3 does not cleave aggrecan in solution at the
Glu373–Ala374 bond. However, since the cysteine
switch mechanism of activation is conserved
across the MMP family, inhibition of activation
would be expected to be similar for all MMPs and
again this is consistent with ‘aggrecanase’
representing a protease having properties in
common with members of the MMP family. Since
the ADAM proteins also possess a propeptide with
a conserved cysteine similar to the MMPs, it is
conceivable that the isothiazolone can also block
this activation, although this is speculative at this
point.
Aggrecan catabolites identified in synovial fluid
of patients with inflammatory joint diseases and
osteoarthritis exhibit N-terminal amino acid
sequences indicating formation by cleavage at the
Glu373–Ala374 ‘aggrecanase’ cleavage site [5, 6]. Our
studies using in vitro cartilage model systems give
further information indicating a selective
up-regulation of specific cleavage at the
‘aggrecanase’ site in response to the cytokines IL-1
and TNF and demonstrate that MMP inhibitors, as
opposed to other anti-arthritic compounds, are
effective in blocking cleavage at the ‘aggrecanase’
site. These data suggest that ‘aggrecanase’ may be
a member of the MMP family or closely related
protease family, and that inhibiting this enzyme
may have utility in preventing cartilage loss in
arthritis.
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